WTTR - Today's Big Lunch Trades 21 Feb 2024

2024-02-21 13:09:13 ET

DENVER, Colo., Feb 21, 2024 (www.247marketnews.com)- Midday Stocks to Watch; (NASDAQ: BREA ), (NASDAQ: VTYX ), (NYSE: WTTR ), (NASDAQ: IOVA ), (NASDAQ: EBS )

News

Brera Holdings’ Strategic Victory: A Leap Forward for Mozambique, Brera Tchumene FC and Global ESG Ambitions- Brera Holdings (NASDAQ: BREA ) is trading at $1.28, up $0.10 (+8.47%), on 1.5M shares.

“Brera Holdings PLC (“Brera Holdings”, “Brera” or the “Company”) is pleased to announce that the strategic acquisition of Manchester United PLC stock last year, which has seen a remarkable 70% increase in value, has accelerated its investment into one of the Company’s professional football teams, Brera Tchumene FC, based in Mozambique. This move underscores Brera Holdings’ commitment to its Environmental, Social, and Governance (ESG) strategy, focusing on social impact and inclusivity in the world of professional football.”

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO- Emergent Biosolutions (NASDAQ: EBS ) is trading at $2.57 (+69.22%) on 57.1M shares.

“Whether it’s increasing access to NARCAN® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver important medical countermeasures to customers around the world, Emergent is providing critical products to address global health crises,” said Mr. Papa. “I am confident that these important products provide for a bright future ahead as Emergent continues to lead in public health preparedness. I look forward to working with the team to accelerate the company’s progress, continue improving its financial position and drive value for shareholders. It is a privilege to join Emergent and chart a new chapter in this vital space.”

SELECT WATER SOLUTIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AD OPERATIONAL UPDATES- Select Water Solutions (NYSE: WTTR ) is trading at $8.98 (+41.03%) on 2.8M shares.

John Schmitz, WTTR’s Chairman, President, and CEO, stated, “The fourth quarter concluded a record-setting year for Select, with full year 2023 consolidated revenue, net income, adjusted EBITDA and operating cash flow all reaching record highs for the Company. With this record operating cash flow, we were able to fund a diverse capital allocation strategy throughout 2023. This included funding our maintenance capex as well as our growth capex plans, particularly around our Water Infrastructure segment, substantially increasing our capital returns to shareholders, by growing our base dividend by 20% during the year and increasing share repurchases, while also executing six bolt-on acquisitions during 2023. Importantly, we were able to do this while also repaying all of our outstanding debt throughout the year and building cash on the balance sheet at year-end.

Momos

Ventyx Biosciences (NASDAQ: VTYX ) is trading at $5.022 (+67.96%), on 75.2M shares.

“Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com .”

Iovance Biotherapeutics (NASDAQ: IOVA ) continues to press forward on the strength of the FDA) approving its AMTAGVI (lifileucel) suspension for intravenous infusion, on Friday afternoon, which we covered when IOVA is trading at $9.6056.

IOVA is trading at $14.87 (+23.62%), on trading volume of 36.7M shares and this morning it hit a high of $15.25.

Its 52-week range is now $3.21 to $15.025, after hitting new 52-week highs Friday afternoon, yesterday, and today. IOVA looks like it wants to take a shot of its April 2022 levels, but will need this strong volume to continue.

The post Today’s Big Lunch Trades 21 Feb 2024 first appeared on 24/7 MarketNews .

For further details see: